Brain cancer is a devastating and life-changing disease. Biomarkers are becoming increasingly important in addressing clinical issues, including in monitoring tumour progression and assessing survival and treatment response. The goal of this study was to identify prognostic biomarkers associated with glioma progression. Discovery proteomic analysis was performed on a small cohort of astrocytomas that were diagnosed as low-grade and recurred at a higher grade. Six proteins were chosen to be validated further in a larger cohort. Three proteins, CA9, CYFIP2, and LGALS3BP, were found to be associated with glioma progression and, in univariate analysis, could be used as prognostic markers. However, according to the results of multivariate analysis, these did not remain significant. These three proteins were then combined into a three-protein panel. This panel had a specificity and sensitivity of 0.7459 for distinguishing between long and short survival. In silico data confirmed the prognostic significance of this panel.
脑癌是一种毁灭性且改变生活的疾病。生物标志物在解决临床问题中日益重要，包括监测肿瘤进展、评估生存期和治疗反应。本研究旨在识别与胶质瘤进展相关的预后生物标志物。我们对一小部分被诊断为低级别但复发时级别更高的星形细胞瘤进行了发现蛋白质组学分析。选择了六种蛋白质在更大的队列中进行进一步验证。研究发现，CA9、CYFIP2和LGALS3BP这三种蛋白质与胶质瘤进展相关，在单变量分析中可作为预后标志物。然而，根据多变量分析的结果，这些标志物未能保持显著性。随后，我们将这三种蛋白质组合成一个三蛋白组合。该组合在区分长生存期和短生存期方面具有0.7459的特异性和敏感性。计算机模拟数据证实了该组合的预后意义。
CA9, CYFIP2 and LGALS3BP—A Novel Biomarker Panel to Aid Prognostication in Glioma
肿瘤(癌症)患者之家